OptiBiotix and Sacco in global push to access probiotics market

OptiBiotix Health (AIM: OPTI) has expanded the terms of a manufacturing, supply and profit sharing deal agreed with Italy’s Sacco and announced in March.

OptiBiotix called the agreement, which will cover both the USA and the rest of the world, “A strategic step to access the US probiotic supplement market, and to extend the opportunities offered by LPLDL into dairy applications.”

The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix' cholesterol and blood pressure reducing LPLDL strain in these territories, in return for 50% of the profit, with a guaranteed cost of manufacture and minimum sales price per kilogramme to secure against discounting.